- A Brief Overview
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Thakur S
. State of The Globe: -A Global Healthcare Threat. J Glob Infect Dis. 2023; 14(4):129-130.
PMC: 9831208.
DOI: 10.4103/jgid.jgid_215_22.
View
2.
Larkin E, Hager C, Chandra J, Mukherjee P, Retuerto M, Salem I
. The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation. Antimicrob Agents Chemother. 2017; 61(5).
PMC: 5404565.
DOI: 10.1128/AAC.02396-16.
View
3.
Kofla G, Ruhnke M
. Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature. Eur J Med Res. 2011; 16(4):159-66.
PMC: 3352072.
DOI: 10.1186/2047-783x-16-4-159.
View
4.
Vila T, Sultan A, Montelongo-Jauregui D, Jabra-Rizk M
. Candida auris: a fungus with identity crisis. Pathog Dis. 2020; 78(4).
PMC: 7371155.
DOI: 10.1093/femspd/ftaa034.
View
5.
Quindos G, Miranda-Cadena K, San-Millan R, Borroto-Esoda K, Canton E, Linares-Sicilia M
. Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of : A European Study. Front Cell Infect Microbiol. 2022; 12:906563.
PMC: 9149255.
DOI: 10.3389/fcimb.2022.906563.
View